Skip to main content
. 2023 Apr 6;9(6):825–834. doi: 10.1001/jamaoncol.2023.0161

Figure 2. Primary and Key Secondary End Points.

Figure 2.

B, Eugonadal progression-free survival (testosterone level ≥150 ng/dL; to convert to nanomoles per liter, multiply by 0.0347) was defined as the time from eugonadal status to disease progression. HR indicates hazard ratio; PD, progressive disease.